GeoVax Labs Announces Participation in Top November Events

Conal Cram
2 Min Read

GeoVax Labs Announces Participation in Top November Events

ATLANTA, GA — In a recent announcement, biotechnological front-runner GeoVax Labs, Inc. (Nasdaq: GOVX), well-esteemed for their trailblazing efforts in developing immunotherapies and vaccines for cancers and infectious diseases, spotlighted their ambitious plans for the upcoming month. GeoVax’s commitment to the biotech space and their participation in these events make them a company to watch in November.

“As a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases, it’s our prerogative to actively engage with the global scientific community. These events provide an invaluable platform for such interactions,” commented David Dodd, Chairman & CEO of GeoVax Labs, Inc.

GeoVax’s November Calendar:

  1. Emerging Growth Conference (Virtual)
    • Date: November 2, 2023, 3:55 p.m. ET
    • Presentation: GeoVax Corporate Update
    • Speaker: David Dodd, Chairman & CEO
  2. BIO-Europe, Munich, Germany
    • Date: November 6-8, 2023
    • GeoVax’s senior management will conduct personalized interactions with attendees.
  3. Vaccines Summit 2023, Boston, MA
    • Date: November 14, 2023, 8:00 a.m. ET
    • Presentation: Insights on MVA-vectored multi-antigen COVID-19 vaccines and their potential against SARS-CoV-2 variants.
    • Speaker: Mukesh Kumar, PhD, Georgia State University
  4. World Vaccine Congress, West Coast, Santa Clara, CA
    • Dates: Sessions spanning from November 27-30, 2023
    • Highlights include discussions on COVID-19 Vaccines for immunocompromised patients and novel vaccine designs against hemorrhagic fevers.

Shining the Spotlight on GeoVax

GeoVax Labs is not just another name in the biotech sector; they are at the forefront, tirelessly pushing the boundaries of science. Their marquee programs, notably their oncolytic gene-directed therapy, Gedeptin®, and their next-generation COVID-19 vaccine, GEO-CM04S1, embody their dedication to advancing healthcare solutions.


As we anticipate GeoVax Labs’ participation in these significant events, it’s evident that their dedication and innovation will continue to shape the future of biotechnology. We invite our readers to share their insights and thoughts on GeoVax’s ventures in the comments below. Let’s foster a vibrant discussion on the future of biotech!

Share This Article
Conal is a seasoned tech industry professional and content writer for numerous tech publications. With a strong background in software engineering and digital media development, he's passionate about sharing the latest updates and insights in the tech industry, particularly in artificial intelligence and other disruptive trends. In his spare time he loves a mezze platter and a good film, and if he's not playing Fortnite or spending time with his daughter you can assume he's at the dry slopes!
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *